Kurk Functional Foods
Overview
We have created the most effective alternative to Ibuprofen, from 100% plants.
Founded by two cancer survivors (and best friends) Dr Harrison Weisinger and Trent Scanlen, we are vertically integrated and are well positioned to scale rapidly into two huge markets worldwide - Herbal medicine ($550B) and Functional Foods ($309B).
After 4 years of R&D in our purpose built lab in Twickenham, we have cleanly distilled curcumin into a micellar emulsion and combined it with other functional plant extracts to create a delicious drink in 3 flavours.
We have achieved over £3.5m in online sales and have pioneered incredible scientific and medical results. We now want to scale our KURK brand, enter retail and unlock distribution partnerships.
Company Highlights
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque.
Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.
Proin neque lacus, semper vel ex at, eleifend rhoncus est.
Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a. Nullam fringilla diam eget dui placerat f
Open an account to get
access to more details
Problem and Solution
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque.
Donec tincidunt, dolor luctus lobortis ul
Open an account to get
access to more details
Competitive Advantage
Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.
Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.
Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.
Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.
Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus b
Open an account to get
access to more details
Current Shareholders & Investors
Cras eleifend purus vitae mattis imperdiet.
Integer fringilla mi ut sem tincidunt, in sagittis odi
Open an account to get
access to more details
See more exiting opportunities on CapitalHQ
Pictor
Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...
ProxyTwin
ProxyTwin™ amplifies expertise. ProxyTwin is a digital twin that works for experts so they can help more people. We create advanced digital replicas of real individuals, enabling them to virtually attend meetings, deliver messages, and hold thousands of interactions simultaneously. Recently...
HorizonTwo Capital Partners
HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.
The Insides Company
First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.
DCARB
We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.
Grabba Technologies Pty Ltd
Advanced manufacturer of biometric identity authorisation products and electronics supplier to defence industry. We invite expressions of interest for up to $10.0M in growth capital.
Backed By Leading Investment Groups and Family Offices
